Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt
Adult Acute Lymphocytic Leukemia
About this trial
This is an interventional treatment trial for Adult Acute Lymphocytic Leukemia focused on measuring CNS relapse, ALL, Treatment
Eligibility Criteria
Inclusion Criteria: proven diagnosis of ALL or very aggressive Non-Hodgkin-Lymphoma (Burkitt/Burkitt-like) and CNS relapse CNS involvement demonstrated by a positive ventricular or lumbar CSF cytology or characteristic signs and symptoms of neoplastic meningitis plus an MRI or CT scan indicating the presence of meningeal involvement in combined relapse in CNS and other locations: systemic therapy with CNS active drugs can be postponed for at least 2 weeks Karnofsky Performance Score is > or = 60% 18 years of age or older free of uncontrolled infection recovered from any grade III / IV toxicities attributable to prior treatment with the exception of hematotoxicity patient not pregnant or breast feeding and effective methods to prevent pregnancy free from severe heart, lung, liver or kidney dysfunction written informed consent Exclusion Criteria: failed to respond (as defined by no clearance of the CSF) to > 1 dose of prior i.th. MTX or ARAC or triple therapy history of neurotoxicity (grade III - IV) attributed to i.th. or systemic HD therapy with MTX or ARAC prior CNS relapse < 1 month before
Sites / Locations
- University Hospital, Medical Dept. II
Arms of the Study
Arm 1
Experimental
Only 1 arm